HDSU catalogue

collections

Data & sample collections

21 collections

  • ALL10

    Protocol ALL 10, protocol voor diagnostiek en behandeling van kinderen en adolescenten (1-19 jaar) met Acute Lymfatische Leukemie (ALL)
    The aim of Protocol ALL-10 is to improve the overall treatment results in terms of EFS and to decrease treatment intensity in patients with a pEFS of >95%. Therapy will be tailored according to the risk of relapse as determined by the MRD levels at 2 time points during the first months of therapy. This tailored therapy should lead to less intensive therapy for patients with low risk of relapse and to intensification of therapy for patients with medium and high risk of relapse.

  • ALL11

    PROTOCOL ALL 11: Treatment study protocol of the Dutch Childhood Oncology Group for Children and adolescents (1-19 year) with newly diagnosed acute lymphoblastic leukemia
    1. To improve the overall outcome as compared to the previous protocols of the DCOG, especially ALL-9 and ALL-10. This is aimed for by decreasing therapy for part of the patients (TEL/AML1, Down syndrome, PPR only), increasing therapy for IKZF1 mutated cases, decreasing the cumulative dose of anthracyclines, omitting cranial irradiation and total body irradiation and individualizing asparaginase therapy for all patients. 2. Does a continuous schedule of Asparaginase lead to less allergic reaction/inactivation of Asparaginase than the standard non continuous schedule of Asparaginase? Patients are randomized to receive noncontinuous PEGasparaginase in IA (induction) and intensification of the Medium Risk group (standard arm A) or to receive continuous PEGasparaginase in IA, IB, M and intensification (continuous arm B) with the same cumulative number of doses of PEGasparaginase. 3. Does prophylactic administration of intravenous immunoglobulins reduce the number of infections during the intensive treatment phases? Patients are randomized in the induction and MR treatment group to receive or not receive prophylactic immunoglobulins. 4. Individualize the dose schedule of asparaginase by therapeutic drug monitoring in order to detect silent inactivation of asparaginase, to prevent allergic/anaphylactic reactions, to switch Asparaginase preparation in time and to prevent too high levels with possible toxicity.

  • Athero- and AAA-Express

    Athero- and Aneurysm-Express Biobank Studies
    The Athero-Express Biobank Study (AE) and the Abdominal Aortic Aneurysm-Express Biobank Study (AAA) are two ongoing, prospective biobank studies initiated in 2002 and 2003, respectively. Together, they comprise detailed histological and clinical data from over 4,500 patients who underwent arterial surgery at two Dutch tertiary referral centers. The AE Biobank includes over 3,500 patients who underwent endarterectomy to remove atherosclerotic plaques, predominantly from the carotid and femoral arteries. The AAA Biobank includes over 1,000 patients who underwent open surgical repair of arterial aneurysms, primarily abdominal aortic aneurysms. For both studies, blood and vascular tissue (plaque or aneurysm wall) were collected during surgery and stored at −80℃. Tissue material is routinely processed for standardised (immuno)histochemical analysis, with histological observations performed by the same dedicated technician, ensuring consistency; interobserver analyses have been previously reported. In AE, the following plaque characteristics were quantified or scored: • Macrophages (CD68) and smooth muscle cells (α-actin) as the percentage of field area using computerised analysis. • Intraplaque vessel density (CD34) as the average count per 3 hotspots. • Intraplaque haemorrhage (IPH) was scored as absent/present using hematoxylin and eosin (HE). • Intraplaque fat was defined as < or ≥40% of total plaque area (HE). • Calcification (HE) and collagen content (picrosirius red) were scored as no/minor vs. moderate/heavy staining. • Overall plaque vulnerability was assessed following the method by Verhoeven et al. In AAA, tissue sections were stained using: • HE, EVG (elastin), picrosirius red (collagen), SMA (smooth muscle cells), CD68 (macrophages), CD3 (T cells), CD20 (B cells), CD138 (plasma cells), and von Willebrand factor (vasa vasorum). • Each marker was semiquantitatively scored from 0 to 3 (0: none, 1: minor, 2: moderate, 3: heavy), separately for the intima, media, and adventitia, across both structural components and immune cell types. For both cohorts, clinical data is obtained through standardised questionnaires, and supplemented with electronic health records where necessary. Ethical approval for this study (TME/C-01.18) was provided by the Medical Research Ethics Committee of University Medical Center Utrecht, Utrecht, The Netherlands on 10 April 2002, and all research was conducted according to the principles of the Declaration of Helsinki (59th amendment, Seoul 2008) and in accordance with the Dutch Medical Research Involving Human Subjects Act (WMO).

  • BioDay

    BioDay Registry
    The BioDay registry is a disease or condition registry for atopic dermatitis (AD)/prurigo nodularis (PN). All patients treated with advanced systemic therapy (biologics and JAK inhibitors [JAKi]) for AD are eligible for inclusion in the prospective, multicenter, observational BioDay registry. Patients are treated in a daily practice setting and the choice of treatment is determined by shared decision making and according to the Dutch AD guidelines. During all visits both clinical outcomes (e.g. EASI, IGA) and patient reported outcomes (e.g. NRS itch, DLQI,ADCT/RECAP) are collected.

  • EPD test

    Electronisch Patienten Dossier - test data
    Het UMC Utrecht is een universitair medisch centrum. Dat betekent dat we meer doen dan alleen zorg verlenen. We leiden de zorgprofessionals van morgen op, doen medisch-wetenschappelijk onderzoek en werken aan vernieuwing van de zorg. Dit is een test entry voor Elektronische Patienten Gegevens.

  • EPIC-NL

    European Prospective Investigation Into Cancer and Nutrition in the Netherlands (EPIC-NL)
    EPIC is the European Prospective Investigation Into Cancer and Nutrition. EPIC-NL is the Dutch contribution to EPIC and comprises about 40,000 individuals prospectively followed since the early 90's. Biological samples have been stored in liquid nitrogen and repeated follow-up of the cohort has occured to obtain detailed information on lifestyle and behavioural factors and morbidity and mortality.

  • HEM-PRO

    Long-term prosthesis survival of total hip and total knee arthroplasty in people with inherited bleeding disorders
    In this single center retrospective cohort study, regular care data of total knee arthroplasty and total hip arthroplasty was extracted from medical records of people with bleeding disorders who attended the Van Creveldkliniek, University Medical Center Utrecht, between 1989 and 2025. Patients with moderate or severe haemophilia A or B (FVIII/FIX <5%) or Von Willebrand’s disease (VWD) with a FVIII activity <5% were included. All types of primary THA or TKA were included. All patients were followed according to standard care. The primary outcome was time to prosthesis failure, defined as revision or indication for revision (but patients are inoperable or refuse), measured in years.

  • JHN

    Julius Huisartsen Netwerk
    The Julius General Practitioners Network (JHN) is a database of primary care routine data. It is a network of approximately seventy general practices with two hundred general practitioners and over 450,000 active patients in the Utrecht area. The database contains data on more than 1.5 million patients from 1995 to the present.

  • MARS

    MARS - Molecular Diagnosis and Risk Stratification of Sepsis
    MARS is a multicenter prospective cohort of ICU patients aimed at developing new molecular technologies for early diagnosis and risk stratification of sepsis. MARS contains comprehensive clinical data (including admission diagnoses, comorbidities, daily treatments, medications, vital-signs, labs, and microbiology results). In addition, daily prospective adjudication of infection plausibility was performed, according to standardized definitions.

  • MOMENTUM

    MOMENTUM-Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac
    MOMENTUM aims to accelerate the technical and clinical development of Anatomic and Biologic MRGRT and facilitate the evidence-based introduction of the MR-Linac into clinical practice. In MOMENTUM, from all adult patients treated on the MR-Linac, technical and clinical data are gathered in order to optimize software, evaluate treatment outcomes, toxicities and progression free, disease free, and overall survival per disease site, and create a repository of anatomical and biological MR sequences to develop new features.

Created with MOLGENIS